Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 11/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7602157 | 1.00 | SLC6A9 (0.67) | SLC6A9OPRD1KDM4ECYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL4136253 | 0.99 | SLC6A9 (0.65) | SLC6A9OPRD1KDM4ECYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL4148441 | 0.99 | SLC6A9 (0.65) | SLC6A9OPRD1KDM4ECYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL4158726 | 0.99 | SLC6A9 (0.65) | SLC6A9OPRD1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL6937064 | 0.90 | CYP1A2 (0.57) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL6937062 | 0.90 | CYP1A2 (0.57) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4439268 | 0.85 | SLC6A9 (0.60) | SLC6A9OPRD1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL7665838 | 0.82 | OPRD1 (0.69) | SLC6A9OPRD1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL6935489 | 0.81 | OPRD1 (0.51) | SLC6A9OPRD1CYP1A2CYP3A4 | |
| SCHEMBL4148214 | 0.81 | CYP1A2 (0.53) | OPRD1CYP1A2CYP3A4CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735383-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2014-05-27 | — | — | US | claimed |
| EP-2041088-B1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC (US) | 2014-01-08 | — | — | EP | claimed |
| US-20120195985-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2012-08-02 | — | — | US | claimed |
| US-20090227595-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | HITCHCOCK STEPHEN | 2009-09-10 | — | — | US | claimed |
| US-7538114-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2009-05-26 | — | — | US | claimed |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | AMGEN INC. | 2008-01-03 | — | — | US | claimed |
| EP-2947067-A1 | Glycine transporter-1 inhibitors | Amgen, Inc (US) | 2015-11-25 | — | — | EP | disclosed |
| EP-2565183-A1 | Glycine transporter-1 inhibitors | Amgen Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227595-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC7A11, SLC6A5 | SLC6A9 8/4885OPRD1 2137/4885KDM4E 3389/4885 |
| US-20120195985-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC6A5, SLC1A2 | SLC6A9 6/4885OPRD1 2031/4885KDM4E 3474/4885 |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | SLC18A2, SLC7A11, SLC6A5 | SLC6A9 8/4885OPRD1 2137/4885KDM4E 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.